Open original FDA record ↗Recall record
- FDA identifier
- Z-0180-2022
- Company in FDA record
- Siemens Healthcare Diagnostics, Inc.
- FDA record creation date
- Oct 28, 2021
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
The firm has confirmed the potential for Atellica CH Urinary/Cerebrospinal Fluid Protein reagent carryover impacting Enzymatic Hemoglobin A1c (A1c_E and A1c_EM) results. Falsely depressed Enzymatic Hemoglobin A1c results may affect consideration of intervention.
Source facts
- Action
- On September 20, 2021, the firm distributed Urgent Medical Device Correction letters to impacted customers. Atellica customers were informed that the resolution of the issue will be implemented in SW v1.25.1. ADVIA customers were informed that the resolution of the issue will be implemented in AP Tool v1.11 and TDef v.1.07. These updates will be available soon. In the interim, customers were provided additional instructions to work around the issue until the update is available. If you have any questions, please contact your Siemens Healthineers Customer Care Center or your local Siemens Healthineers technical support representative.
- Initiated
- 2021-09-20
- Root cause
- Software design
- Distribution
- Worldwide distribution - US Nationwide distribution.
- Recall number
- Z-0180-2022
- Recall status
- Open, Classified
- CDRH record ID
- 189522
- FDA record created
- 2021-10-28
- Recall event number
- 88784